Cytokinetics Piotroski F Score

CYTK
 Stock
  

USD 41.00  1.71  4.35%   

This module uses fundamental data of Cytokinetics to approximate its Piotroski F score. Cytokinetics F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Cytokinetics. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Cytokinetics financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Continue to Cytokinetics Altman Z Score, Cytokinetics Correlation, Cytokinetics Valuation, as well as analyze Cytokinetics Alpha and Beta and Cytokinetics Hype Analysis.
  
Refresh
Cytokinetics Issuance Repayment of Debt Securities is as compared to previous years. The last year's value of Issuance Repayment of Debt Securities was reported at 140.51 Million. The current Debt to Equity Ratio is estimated to increase to 2.64, while Long Term Debt to Equity is projected to decrease to 0.56. Cytokinetics Revenue to Assets are decreasing as compared to previous years. The last year's value of Revenue to Assets was reported at 0.08. The current Total Assets Per Share is estimated to increase to 10.71, while Cash and Equivalents Turnover is projected to decrease to 0.67.
At this time, it appears that Cytokinetics' Piotroski F Score is Poor. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
4.0
Piotroski F Score - Poor
1
Current Return On AssetsNegativeFocus
2
Change in Return on AssetsDecreasedFocus
3
Cash Flow Return on AssetsNegativeFocus
4
Current Quality of Earnings (accrual)ImprovingFocus
5
Asset Turnover GrowthIncreaseFocus
6
Current Ratio ChangeIncreaseFocus
7
Long Term Debt Over Assets ChangeHigher LeverageFocus
8
Change In Outstending SharesDecreaseFocus
9
Change in Gross MarginNo ChangeFocus

Cytokinetics Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Cytokinetics is to make sure Cytokinetics is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Cytokinetics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Cytokinetics' financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares65.4 M76.9 M
Fairly Down
Increasing
Slightly volatile
Weighted Average Shares Diluted65.6 M76.9 M
Fairly Down
Increasing
Slightly volatile
Net Cash Flow from Operations(146.3 M)(142.5 M)
Fairly Down
Decreasing
Slightly volatile
Total Assets907.7 M841.3 M
Significantly Up
Increasing
Slightly volatile
Total Liabilities644.6 M597.5 M
Significantly Up
Increasing
Slightly volatile
Current Assets578 M535.7 M
Significantly Up
Increasing
Slightly volatile
Current Liabilities77.5 M71.9 M
Significantly Up
Increasing
Slightly volatile
Total Debt291.2 M269.9 M
Significantly Up
Increasing
Slightly volatile
Return on Average Assets(0.33)(0.306)
Significantly Down
Increasing
Slightly volatile
Gross Margin0.890.9
Fairly Down
Decreasing
Slightly volatile
Asset Turnover0.150.1
Way Up
Decreasing
Very volatile

Cytokinetics F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Cytokinetics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Cytokinetics in a much-optimized way.

About Cytokinetics Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Book Value per Share

2.59

Share
Cytokinetics Book Value per Share is decreasing as compared to previous years. The last year's value of Book Value per Share was reported at 3.17

Cytokinetics Current Valuation Drivers

We derive many important indicators used in calculating different scores of Cytokinetics from analyzing Cytokinetics' financial statements. These drivers represent accounts that assess Cytokinetics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cytokinetics' important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee(932.77 K)(817.61 K)(780.08 K)(689.9 K)(586.69 K)(633 K)
Revenue Per Employee97.58 K242.31 K172.23 K302.58 K191.9 K212.66 K
Average Assets306.78 M242.16 M218.51 M374.25 M702.56 M758.02 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(122.85 M)(101.25 M)(113.78 M)(109.5 M)(196.6 M)(201.77 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(122.85 M)(101.25 M)(113.78 M)(109.5 M)(196.6 M)(201.77 M)
Earnings before Tax(127.79 M)(106.29 M)(121.69 M)(127.29 M)(215.31 M)(220.98 M)
Average Equity131.82 M63.19 M(8.08 M)34.8 M144.3 M116.66 M
Enterprise Value353.14 M360.05 M639.82 M1.41 B3.99 B4.3 B
Free Cash Flow(104.64 M)(102.09 M)(93.53 M)(2.11 M)(191.39 M)(196.43 M)
Invested Capital168.94 M189.91 M363.43 M558.56 M926.72 M999.89 M
Invested Capital Average203.78 M194.17 M230.69 M388.78 M814.76 M879.08 M
Market Capitalization439.16 M345.77 M626.86 M1.47 B3.82 B4.13 B
Tangible Asset Value294.81 M211.18 M289.81 M533.8 M841.32 M907.74 M
Working Capital241.85 M185.48 M207.73 M443.02 M463.81 M500.43 M

About Cytokinetics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Cytokinetics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cytokinetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cytokinetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company was incorporated in 1997 and is headquartered in South San Francisco, California. Cytokinetics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 253 people.

Cytokinetics Investors Sentiment

The influence of Cytokinetics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Cytokinetics. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Cytokinetics Implied Volatility

    
  95.75  
Cytokinetics' implied volatility exposes the market's sentiment of Cytokinetics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Cytokinetics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Cytokinetics stock will not fluctuate a lot when Cytokinetics' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Cytokinetics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Cytokinetics' short interest history, or implied volatility extrapolated from Cytokinetics options trading.

Current Sentiment - CYTK

Cytokinetics Investor Sentiment

Most of Macroaxis users are currently bullish on Cytokinetics. What is your opinion about investing in Cytokinetics? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish

Pair Trading with Cytokinetics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cytokinetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytokinetics will appreciate offsetting losses from the drop in the long position's value.

Cytokinetics Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to Cytokinetics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cytokinetics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cytokinetics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cytokinetics to buy it.
The correlation of Cytokinetics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cytokinetics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cytokinetics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cytokinetics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Cytokinetics Altman Z Score, Cytokinetics Correlation, Cytokinetics Valuation, as well as analyze Cytokinetics Alpha and Beta and Cytokinetics Hype Analysis. Note that the Cytokinetics information on this page should be used as a complementary analysis to other Cytokinetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for Cytokinetics Stock analysis

When running Cytokinetics price analysis, check to measure Cytokinetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytokinetics is operating at the current time. Most of Cytokinetics' value examination focuses on studying past and present price action to predict the probability of Cytokinetics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cytokinetics' price. Additionally, you may evaluate how the addition of Cytokinetics to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Is Cytokinetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
3.5 B
Quarterly Revenue Growth YOY
-0.82
Return On Assets
-0.19
Return On Equity
-2.8
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine Cytokinetics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.